Clinical trial NCT05364541: MyoVista wavECG Clinical Evaluation: >=60 y/o Enrichment Population
Official title: MyoVista wavECG Clinical Evaluation: >=60 y/o Enrichment Population
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Health Screening
Lead sponsor: Heart Test Laboratories, Inc.
Sponsor class: INDUSTRY
First posted: 2022-05-06
Enrollment: 50
Sex: ALL
Minimum age (years): 60
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SCREENING

Brief summary: This is a single-center, interventional, single arm clinical study of the MyoVista wavECG for the detection of LV relaxation abnormalities. The study will be conducted at a single investigational site within the United States. Study subjects will predominately be screened from among those who have been enrolled in prior registry studies by the institution.

Detailed description: The study has a planned enrollment of at least 50 subjects to obtain approximately 40 subjects with a "normal" septal and lateral e' value on echocardiogram. The criteria defined as septal e'\< 7 cm/s or lateral e'\< 10 cm/s for relaxation abnormality based on ASE/AECVI guidelines will be used for the evaluation of LV diastolic function which is associated with abnormal relaxation in echocardiography. An independent Core Lab will verify all septal and lateral e' values on the site-acquired echocardiograms and these Core Lab measurements will serve as the ground truth standard with regard to the presence of LV relaxation abnormalities.

Analysis of data from a prior multi-center study has revealed good correlation between the MyoVista wavECG results and echocardiography for the presence of LV relaxation abnormalities. This current study (HS-CLINVAL-002) is intended to supplement data collected in prior and ongoing studies, namely HS-CLINVAL-001, by recruiting individuals who are \>60 years old and who are anticipated to have normal echocardiogram results based on a screening of selected clinical characteristics. Subjects in this study will be invited to participate and receive non-standard-of-care echocardiograms and a study driven MyoVista test.

The study will continue to focus on LV relaxation abnormalities by gathering additional device validation data for the purposes of regulatory approval peer-reviewed publications. Echocardiograms of study subjects will be used to compare/validate the study findings.

Eligibility criteria: Inclusion Criteria:

* Subject is \>=60 years of age
* Subjects will predominately be recruited among those who are already enrolled in existing registry studies within the institution.
* The subject provides written informed consent using an Informed Consent Form that is reviewed and approved by the site's Institutional Review Board (IRB).
* Conventional ECG results show a sinus rhythm and no other contraindicated rhythm abnormalities (see exclusions below).

Exclusion Criteria:

* The subject has current acute coronary syndrome, decompensated heart failure or stroke
* The subject has received any prior cardiac interventions or surgical therapeutic procedures relating to cardiac abnormalities: valve replacement, pacemaker implantation, coronary artery bypass grafting (CABG), heart transplant, ablation, coronary stent placement, etc.
* Conventional ECG results indicating a lack of sinus rhythm and/or any other contraindicated rhythm abnormalities, including: active atrial fibrillation or atrial flutter, left anterior fascicular block, left and/or right bundle branch block
* The subject is pregnant at the time of the study testing
* The subject has chest deformities that interfere with accurate measurement of ECG (either conventional or wavECG)
* Subjects with central nervous system or musculoskeletal abnormalities that may interfere with accurate acquisition of ECG and/or echocardiogram measurements.
* The subject is enrolled in another clinical study that may interfere with MyoVista or echocardiogram measurements. Exceptions to this may be approved by HeartSciences.

Primary outcomes:
measure: Diagnostic Performance
timeFrame: Baseline
Secondary outcomes:
Other outcomes:
Locations:
city: Dallas
country: United States
facility: University of Texas Medical Center
state: Texas
Study officials:
affiliation: Rutgers Robert Wood Johnson Medical School
name: Partho Sengupta, MD
role: PRINCIPAL_INVESTIGATOR
References: